Echocardiographic study of the haemodynamic effects of remifentanil with and without glycopyrrolate in healthy childre
- Conditions
- ASA I and II children
- Registration Number
- EUCTR2006-000460-90-BE
- Lead Sponsor
- niversity Hospital Ghent
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
ASA I and II male and female patients, aged 1-6 years, scheduled for urological surgery
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
children with cardiac disease and diabetes
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Remifentanil is a short acting mu opioid agonist used in general anaesthesia. Its use induces bradycardia and possibly hypotension. By associating glycopyrrolate, these side effects can be countered. This study evaluates the haemodynamic effects of this combination in healthy children by means of transthoracic echocardiography in order to determine the influence of preload, afterload and cardiac contractility.;Secondary Objective: ;Primary end point(s): Measure the effect of glycopyrrolate and remifentanil on cardiac contractility, preload and afterload, and blood pressure.
- Secondary Outcome Measures
Name Time Method